GHRS Fundamental Analysis - GH RESEARCH PLC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to GHRS. GHRS was compared to 194 industry peers in the Pharmaceuticals industry. While GHRS seems to be doing ok healthwise, there are quite some concerns on its profitability. GHRS is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GHRS has reported negative net income.

GHRS had negative earnings in each of the past 5 years.

GHRS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

GHRS's Return On Assets of -13.14% is fine compared to the rest of the industry. GHRS outperforms 66.49% of its industry peers.

Looking at the Return On Equity, with a value of -13.57%, GHRS is in the better half of the industry, outperforming 75.26% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-13.14%
ROE	-13.57%
ROIC	N/A

ROA(3y)-15.08%

ROA(5y)-11.23%

ROE(3y)-15.67%

ROE(5y)-11.65%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GHRS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GHRS has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for GHRS has been increased compared to 5 years ago.

GHRS has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 54.46 indicates that GHRS is not in any danger for bankruptcy at the moment.

GHRS has a better Altman-Z score (54.46) than 96.39% of its industry peers.

GHRS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

With a decent Debt to Equity ratio value of 0.00, GHRS is doing good in the industry, outperforming 61.86% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	54.46

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

GHRS has a Current Ratio of 29.71. This indicates that GHRS is financially healthy and has no problem in meeting its short term obligations.

GHRS has a better Current ratio (29.71) than 96.91% of its industry peers.

GHRS has a Quick Ratio of 29.71. This indicates that GHRS is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 29.71, GHRS belongs to the best of the industry, outperforming 96.91% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	29.71
Quick Ratio	29.71

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GHRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.42%.

EPS 1Y (TTM)-27.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-26.67%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

GHRS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -12.75% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-27.5%

EPS Next 2Y-46.12%

EPS Next 3Y-26.71%

EPS Next 5Y-12.75%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GHRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GHRS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

GHRS's earnings are expected to decrease with -26.71% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-46.12%

EPS Next 3Y-26.71%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GHRS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GH RESEARCH PLC

NASDAQ:GHRS (7/29/2025, 8:00:01 PM)

After market: 14.97 0 (0%)

14.97

-0.01 (-0.07%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-08 2025-05-08/bmo

Earnings (Next)08-20 2025-08-20

Inst Owners68.88%

Inst Owner Change0.05%

Ins Owners33.88%

Ins Owner ChangeN/A

Market Cap928.59M

Analysts84.29

Price Target33.81 (125.85%)

Short Float %6%

Short Ratio9.5

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)41.87%

Min EPS beat(2)31.51%

Max EPS beat(2)52.24%

EPS beat(4)4

Avg EPS beat(4)27.21%

Min EPS beat(4)10.34%

Max EPS beat(4)52.24%

EPS beat(8)7

Avg EPS beat(8)28.59%

EPS beat(12)10

Avg EPS beat(12)28.85%

EPS beat(16)14

Avg EPS beat(16)33.53%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)4.98%

PT rev (3m)4.04%

EPS NQ rev (1m)5.9%

EPS NQ rev (3m)59.99%

EPS NY rev (1m)1.32%

EPS NY rev (3m)1.61%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.99
P/tB	2.99
EV/EBITDA	N/A

EPS(TTM)-0.79

EYN/A

EPS(NY)-1.6

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0

BVpS5

TBVpS5

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-13.14%
ROE	-13.57%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-15.08%

ROA(5y)-11.23%

ROE(3y)-15.67%

ROE(5y)-11.65%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	29.71
Quick Ratio	29.71
Altman-Z	54.46

F-ScoreN/A

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)62.43%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-27.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-26.67%

EPS Next Y-27.5%

EPS Next 2Y-46.12%

EPS Next 3Y-26.71%

EPS Next 5Y-12.75%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-22.05%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-15.36%

EBIT Next 3Y-17.86%

EBIT Next 5Y-14.22%

FCF growth 1Y-26.61%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-26.84%

OCF growth 3YN/A

OCF growth 5YN/A

GH RESEARCH PLC (GHRS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens